제품 > 항체 > Biosimilar Antibody

Human Trop-2 Monoclonal Antibody（N301Q） (YR0019)

Human Trop-2 ELISA Standard Curve. Direct ELISA binding curve demonstrating the recognition of Human Anti-Human Trop-2 (Research Grade Sacituzumab（N301Q）Biosimilar) Monoclonal Antibody to CD19. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.

Human Trop-2 SPR assay. Determined through SPR assay, the Human Anti-Human Trop-2 (Research Grade Sacituzumab（N301Q）Biosimilar) Monoclonal Antibody is Capable of binding to Human Trop-2 with an affinity constant of 20.45 nM.

Basic Information

Clone	Sacituzumab Biosimilar
Molecular Weight	150 kDa
Endotoxin	<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay
Sterility	0.2 μm filtration
Aggregation	<5% Determined by SECP
Purity	>95% Determined by SDS-PAGE

Product Information

Production	Purified from cell culture supernatant in an animal-free facility
Purification	Protein A or G purification
Storage	2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Target Background

Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2.Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.